The U.S. Food and Drug Administration has announced safety reviews of the FDA-approved medications Regranex Gel, Ziagen and Videx.
The FDA said study data suggests there might be an increased risk of death from cancer in diabetic patients using Regranex (becaplermin) Gel to treat leg and foot ulcers.
The FDA said it was also studying data that indicate a higher risk of heart attack in patients infected with the human immunodeficiency virus who take Ziagen (abacavir) or Videx (didanosine) as part of their drug therapy.
Until all three reviews are completed, the FDA said health care professionals should evaluate the potential risks and benefits of each drug with their patients.
Copyright 2008 by United Press International
Related stories:
Marketing of unproven genetic tests a threat to public health
No mechanism currently exists to ensure that genetic tests are supported by adequate evidence before they go to market, or that marketing claims are truthful and not misleading, according to a policy analysis to be published April 4 in
Science. Misleading claims about genetic tests may lead health-care providers and patients to make inappropriate decisions about which tests to take and how to use genetic tests that have potential for profound medical consequences, the authors argue.
OTC cough medicine: Not worthwhile for children or adults?
Alert parents know that small children should not take over-the-counter cough medications. Now researchers say the stuff might not help adults much, either.
Selective reporting of antidepressant trials exaggerates drug effectiveness
Selective publication in reporting results of antidepressant trials exaggerates the effectiveness of the drugs, according to a report in the January 17 issue of the
New England Journal of Medicine. The report’s primary author is Erick Turner, M.D., assistant professor of psychiatry, physiology and phamacology at Oregon Health & Science University (OHSU) and Medical Director of the Portland Veterans Affairs Medical Center’s Mood Disorders Program.
Tumors use enzyme to recruit regulatory T-cells and suppress immune response
One way tumors fly under the radar of the immune system is by using IDO, an enzyme used by fetuses to help avoid rejection, to recruit powerful regulatory T cells that turn down the immune response, researchers say.
Withdrawn MS drug returns to market
Just months after receiving FDA approval, natalizumab, a medication for the treatment of multiple sclerosis (MS) and other inflammatory disorders, was voluntarily withdrawn by its manufacturers after three patients developed a brain infection known as Progressive Multifocal Leukoencephalopathy (PML).
FDA will look into scientist's possible conflict
(AP) -- Federal health officials said Tuesday they will look into a possible conflict of interest involving a prominent toxicologist who is heading up a review of a sensitive safety issue.
States ask baby product companies to avoid BPA
(AP) -- Attorneys general from Connecticut, New Jersey and Delaware sent letters Friday to 11 companies that make baby bottles and baby formula containers, asking they no longer use the chemical bisphenol A in their manufacturing because they said it was potentially harmful to infants.
Limit on cold remedies for kids was FDA's idea
(AP) -- When drug makers made a surprise announcement this week that they no longer recommend cough and cold remedies for youngsters under 4, they didn't let on that it was the government's idea.